Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Ireland
  4. Irish Stock Exchange
  5. Elan Corporation Ltd
  6. News
  7. Summary
    DRX   IE0003072950

ELAN CORPORATION LTD

(DRX)
SummaryChartsNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exclusive - TPG-backed Aptalis Pharma hires banks for an IPO: sources

10/23/2013 | 05:01pm EDT
David Bonderman, Founding Partner, TPG Capital takes part in a panel discussion titled

NEW YORK (Reuters) - Aptalis Pharma Inc, a specialty drug maker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter said on Wednesday.

Goldman Sachs Group Inc (>> Goldman Sachs Group Inc) and JPMorgan Chase & Co (>> JPMorgan Chase & Co.) will lead the offering, which might not happen until next year, the people said on condition of anonymity because the discussions are private.

Representatives for TPG, Aptalis, Goldman Sachs and JPMorgan did not immediately respond to requests for comment.

Bridgewater, New Jersey-based Aptalis makes drugs to treat gastroenterology and cystic fibrosis. It had revenues of about $530 million (327.8 million pounds) for the nine months ending June 30, according to Moody's Investors Service Inc.

Buyout firm TPG bought the drug maker, formerly known as Axcan Pharma, for $1.3 billion in 2008 and merged it with Eurand Pharmaceuticals in 2011. The combined company was renamed Aptalis.

Looking to ride a wave of deal making in specialty pharma, TPG held unsuccessful discussions to sell Aptalis earlier this year with a number of companies, including Elan Corp (>> Elan Corporation, plc), Forest Laboratories Inc (>> Forest Laboratories, Inc.) and Sun Pharmaceutical Industries Ltd (>> Sun Pharmaceutical Industries Limited), people familiar with the matter told Reuters in August.

A sale failed to materialize not just because of TPG's price expectations of between $3 billion and $4 billion, which buyers found expensive, but also because of the changed circumstances for some prospective buyers, the people said at that time.

Elan agreed in July to sell itself to U.S. drug maker Perrigo Co (>> Perrigo Company) for $8.6 billion, while Forest announced in May that its long-time chief executive would retire at the end of the year.

Last month, Aptalis arranged a loan with banks to refinance debt and pay a dividend to TPG. Following push back from the lenders, the loan was downsized to $1.25 billion from $1.4 billion, making the dividend $400 million instead of $550 million as originally planned, according to Thomson Reuters Loan Pricing Corp.

It is still possible that a sale of Aptalis occurs, even as the company heads towards a stock market flotation.

Neiman Marcus, another TPG portfolio company, registered for an IPO before it agreed to be sold to a private equity consortium for $6 billion last month.

TPG was an investor in upscale retailer Neiman Marcus along with fellow buyout firm Warburg Pincus LLC, which also sold another one of its portfolio companies this year after filing plans to take it public. That company, Bausch & Lomb Holdings Inc was taken over in August by Valeant Pharmaceuticals International (>> Valeant Pharmaceuticals Intl Inc) for $8.7 billion.

(Reporting by Olivia Oran, Soyoung Kim and Greg Roumeliotis in New York. Editing by Andre Grenon)

By Olivia Oran, Soyoung Kim and Greg Roumeliotis


© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
SUN PHARMACEUTICAL INDUSTRIES LTD. -0.64% 835.9 Delayed Quote.42.03%
THE GOLDMAN SACHS GROUP, INC. 1.88% 413.69 Delayed Quote.53.98%
THE LEAD CO., INC. -1.28% 695 End-of-day quote.-17.26%
All news about ELAN CORPORATION LTD
2014With eye on tax rates, Horizon Pharma buys Ireland's Vidara
RE
2013Ex-SAC manager Martoma fails to end part of insider case
RE
2013ELAN CORPORATION, PLC : Perrigo Company and Elan Corporation Plc Receive Irish High Court ..
PU
2013Ex-SAC trader points to Cohen testimony in insider trading case
RE
2013ELAN CORPORATION, PLC : Elan Announces Shareholder Approval of its Acquisition by Perrigo ..
BU
2013Elan wins shareholder approval to complete Perrigo sale
RE
2013The prosecutors with SAC Capital in their crosshairs
RE
2013ELAN CORPORATION, PLC : Elan Reports Third Quarter 2013 Financial Results
BU
2013EXCLUSIVE - TPG-BACKED APTALIS PHARM : sources
RE
2013ELAN CORPORATION, PLC : Elan Announces Webcast of Third Quarter 2013 Financial Results
BU
More news
Analyst Recommendations on ELAN CORPORATION LTD
More recommendations
Chart ELAN CORPORATION LTD
Duration : Period :
Elan Corporation Ltd Technical Analysis Chart | DRX | IE0003072950 | MarketScreener
Sector and Competitors
1st jan.Capi. (M$)
ELAN CORPORATION LTD0.00%0
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-39.69%25 414